Ethanol septal ablation for refractory ventricular tachycardia

Area of Science:

• Cardiology
• Interventional Cardiology
• Cardiac Pathology

Background:

• Severe ischemic or nonischemic cardiomyopathy frequently presents with recurrent ventricular arrhythmias.
• While many ventricular arrhythmias are asymptomatic and managed with medications like beta-blockers or amiodarone, a subset requires advanced therapies such as antitachycardic pacing, internal defibrillation, or radiofrequency ablation.

Observation:

• A patient with end-stage nonischemic cardiomyopathy experienced recurrent ventricular tachycardia (VT) refractory to medical management and standard VT radiofrequency ablation (VTRFA).
• The patient underwent successful ethanol septal ablation (ESA) to eliminate the arrhythmia source, followed by cardiac transplantation five days later.

Findings:

• Ethanol septal ablation (ESA) proved effective in treating drug-refractory and procedure-refractory ventricular tachycardia (VT) in a patient with end-stage nonischemic cardiomyopathy.
• The case provides a unique opportunity to study the acute pathological and histological changes following ESA.

Implications:

• Ethanol septal ablation (ESA) represents a potential therapeutic option for highly refractory ventricular tachycardia (VT) in select cardiomyopathy patients.
• This case highlights the importance of exploring novel ablation techniques for complex arrhythmias and offers valuable insights into the tissue response to ESA.